Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

Hypercholesterolemia Clinical Trial

— CEPHEUS  

Official title:

Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01604733
• Other study ID #: NIS-EG-CRE-2010/01
• Status: Completed
• Phase: N/A
• First received: May 21, 2012
• Last updated: May 23, 2012
• Start date: October 2010
• Est. completion date: June 2011

Study information

• Verified date: May 2012
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Egypt: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Study objective is to evaluate the level of control of hypercholesterolemia in Egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).

Description:

Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1000
• Est. completion date: June 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years and above on current lipid lowering drug for at least 3 months with no dose change for a minimum of 6 weeks

• Subject must provide informed consent and comply with the survey procedures

Exclusion Criteria:

• Less than 18 years less than 3 months on antidyslipidemic agent Subjects who are unwilling or unable to provide informed consent

Study Design

Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Hypercholesterolemia

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , overall and by country		24 weeks	No
Secondary	The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes		24 weeks	No
Secondary	The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Third Joint European Task Force guideline, in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes		24 weeks	No
Secondary	Determinants (e.g. patient and physician characteristics , country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia		24 weeks	No
Secondary	Physician characteristics associated with the allocation of treatment regimen.		24 weeks	No
Secondary	The proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the sub-population patients with fasting triglycerides<200 mg/d		24 weeks	No